Embed
Email

Cancer Immunology Basic Mechanisms Behind Tumor Rejection And ...

Document Sample

Shared by: niusheng11
Categories
Tags
Stats
views:
0
posted:
12/3/2011
language:
English
pages:
3
International Summer Science Institute Young@Science, Weizmann Institute of Science







Cancer Immunology Basic Mechanisms Behind Tumor

Rejection And Tumor Growth



Mentor: Ofir Goldberger

Supervisor: Prof. Lea Eisenbach

Dept. of Immunology

Address: Wolfson bldg. room 220, Tel: 2881

E-mail: ofir.goldberger@weizmann.ac.il





Background

Malignant cancer is defined by the NIH as abnormal cells which divide without

control or order and may invade and damage other tissues and organs.

The adaptive cellular immune system is theoretically capable of discriminating

between transformed (tumor) cells and normal tissue cells and subsequently attacking

the tumor cells. The main participants in this scenario are white blood cells called

lymphocytes. A population of lymphocytes called T cells can identify the tumor by

recognizing a short protein sequence (called a peptide) presented on top of a special

molecule (MHC class I) on the cell surface. The T cells perform this interaction via

the T cell receptor (TCR) which can recognize only one such peptide-MHC complex.

Since there are billions of different T cells in our bodies, each individual possesses the

potential to recognize at least that many different peptides.

The ability of T cells to kill tumor cells has been shown in numerous scenarios

in-vitro as well as in-vivo in mice. However, attempts to use lymphocytes for cancer

immunotherapy in patients have, so far, been mostly unsuccessful.





Research Goal

The predominant dogma predicts that increasing the number of T cells that can

recognize (and potentially kill) tumor cells will lead to the eradication of the tumor.

Under this assumption, much effort has been directed by the research community at

methods which may increase the number of such tumor-specific T cells. Such

methods include various immunization techniques and other ex-vivo treatments of







1

www.weizmann.ac.il/young

International Summer Science Institute Young@Science, Weizmann Institute of Science





T cells. However, our lab showed that increasing the number of tumor specific T cells

even to 100% of the total T cell population is not sufficient to destroy the tumor.

We have identified a tumor escape mechanism known as antigen silencing, which

occurs in the tumor model we investigate. We now seek to better characterize this

antigen silencing mechanism both at the DNA level and by describing the kinetics of

this phenomena.





Methodology

To study this lymphocyte – tumor interaction, we employ a transgenic mouse / tumor

system:

Transgenic tumor: The MO5 mouse melanoma (skin cancer) tumor cell line has been

transfected with the chicken ovalbumin gene. This tumor expresses an ovalbumin

derived peptide SIINFEKL which binds to an MHC class I molecule of type H-2Kb

with very high affinity.

Transgenic mouse: Mice of a strain called OT-I are transgenic to the T cell receptor

which recognizes the SIINFEKL peptide when it is presented on the H-2Kb MHC

class I molecule.





A scenario can be envisioned in which the OT-I T cells recognize the SIINFEKL

peptide on the H-2Kb molecule on the surface of the MO5 tumor and kill it. The

prediction from this simple model is, therefore, that an MO5 tumor cannot be

implanted in an OT-I mouse. However, this prediction was proven false by us and

opened a window into the question of tumor – T cell interactions and immune escape

by the tumor.





Tentative Research Plan

1. We will remove tumor grown on OT-I mice and investigate antigen silencing by

RT-PCR (Reverse Transcription Polymerase Chain Reaction).

2. We will perform a series of FACS (Fluorescence Activated Cell Sorting)

experiments to detect localization of T cells in tumor bearing mice.

• This research plan is tentative and partial since new and current data dictates the

experiment flow.

• Some work with mice may be involved but is not compulsory.





2

www.weizmann.ac.il/young

International Summer Science Institute Young@Science, Weizmann Institute of Science





Recommended Readings

Cancer immunotherapy: moving beyond current vaccines. Rosenberg SA, Yang JC,

Restifo NP. Nat Med. 2004 Sep;10(9):909–15.

Human tumor-specific T lymphocytes: does function matter more than number? Curr

Opin Immunol. 2005 Jun;17(3):320–5.





Note: Read the papers well but do not dwell into details, rather focus on

comprehending the basic mechanisms at work.









3

www.weizmann.ac.il/young



Related docs
Other docs by niusheng11
CIOFF-Groups-Report-2010
Views: 419  |  Downloads: 0
stockmkt
Views: 0  |  Downloads: 0
DIFFERENTIAL FLOAT CONTROL VALVE DIFL
Views: 3  |  Downloads: 0
travelrite_nzd
Views: 0  |  Downloads: 0
Office location checklist
Views: 2  |  Downloads: 0
You can help NNAAMI with
Views: 0  |  Downloads: 0
Carey Road CRD Lands
Views: 11  |  Downloads: 0
By registering with docstoc.com you agree to our
privacy policy

You are almost ready to download!

You are almost ready to download!